PLAT and cancer: A total of 385 patients were enrolled in this study after excluding patients who were diagnosed with hemorrhagic stroke (n = 91), TIA (n = 41), undergoing malignancy treatment (n = 56), mRS ≥ 3 (n = 46), or receiving intravenous tissue plasminogen activator treatment and endovascular treatment (n = 42) (Fig. 1).